Chugai Pharmaceutical Co.... (CHGCF)
OTC: CHGCF
· Real-Time Price · USD
39.99
-3.97 (-9.03%)
At close: Aug 15, 2025, 2:46 PM
39.99
0.00%
After-hours: Aug 14, 2025, 08:00 PM EDT
Chugai Pharmaceutical Income Statement
Financials in JPY. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1,084.6B | 1,036.1B | 1,111.4B | 1,276B | 1,243.4B | 1,211.6B | 1,259.9B | 1,143.7B | 1,205.7B | 1,191.5B | 999.76B | 887.92B | 809.05B | 776.34B |
Cost of Revenue | 331.21B | 334.93B | 413.31B | 534.15B | 525B | 513.16B | 476.25B | 373.9B | 409B | 397.23B | 338.15B | 299.86B | 265.02B | 267.53B |
Gross Profit | 753.36B | 701.15B | 698.06B | 741.89B | 718.44B | 698.48B | 783.7B | 769.82B | 796.7B | 794.26B | 661.61B | 588.06B | 544.03B | 508.81B |
Operating Income | 480.9B | 435.19B | 431.94B | 467.07B | 457.27B | 444.6B | 533.31B | 522.9B | 548.17B | 544.94B | 421.9B | 356.75B | 321.28B | 292.79B |
Interest Income | 495M | 1.4B | 2.76B | 2.76B | 2.76B | 2.16B | 2.4B | 2.4B | 2.4B | 1.61B | n/a | n/a | n/a | n/a |
Pretax Income | 488.86B | 444.05B | 443.82B | 470.35B | 457.9B | 444.62B | 531.17B | 520.39B | 545.05B | 541.35B | 419.38B | 354B | 319.88B | 291.21B |
Net Income | 355.04B | 326.37B | 325.47B | 336.75B | 326.97B | 316.15B | 374.43B | 370.79B | 389.01B | 387.36B | 303B | 256.46B | 230.58B | 210.61B |
Selling & General & Admin | 101.6B | 107.55B | 107.38B | 112.7B | 107.75B | 96.52B | 100.76B | 104.72B | 106.84B | 107.89B | 102.42B | 98.99B | 96.49B | 94.55B |
Research & Development | 171.63B | 173.27B | 174.87B | 178.24B | 169.38B | 158.63B | 149.63B | 142.2B | 141.69B | 141.44B | 137.3B | 132.32B | 126.27B | 121.48B |
Other Expenses | -603M | n/a | n/a | 267M | 267M | 267M | 267M | 259M | 259M | 255M | 255M | -361M | -624M | -968M |
Operating Expenses | 272.47B | 265.96B | 266.13B | 274.82B | 261.17B | 253.88B | 250.39B | 246.92B | 248.53B | 249.33B | 239.72B | 231.32B | 222.76B | 216.02B |
Interest Expense | 15M | 24M | 26M | 544M | 552M | 558M | 570M | 1B | 998M | 995M | 993M | 56M | 63M | 62M |
Selling & Marketing Expenses | 108.2B | 114.15B | 112.58B | 104.86B | 96.14B | 81.38B | 77.15B | 78.46B | 78.09B | 77.51B | 76.59B | 75.05B | 73.55B | 72.69B |
Cost & Expenses | 603.67B | 600.89B | 679.43B | 808.98B | 786.16B | 767.03B | 726.64B | 620.82B | 657.53B | 646.56B | 577.86B | 531.17B | 487.78B | 483.55B |
Income Tax Expense | 133.82B | 117.68B | 118.35B | 133.6B | 130.93B | 128.47B | 156.74B | 149.6B | 156.04B | 153.99B | 116.39B | 97.53B | 89.3B | 80.6B |
Shares Outstanding (Basic) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B |
Shares Outstanding (Diluted) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.64B | 1.65B | 1.65B | 1.65B |
EPS (Basic) | 215.77 | 198.37 | 197.83 | 204.70 | 198.76 | 192.19 | 227.65 | 225.46 | 236.56 | 235.58 | 184.28 | 155.99 | 140.26 | 128.13 |
EPS (Diluted) | 215.75 | 198.34 | 197.80 | 204.65 | 198.72 | 192.15 | 227.57 | 225.37 | 236.44 | 235.44 | 184.17 | 155.88 | 140.15 | 128.01 |
EBITDA | 488.37B | 444.06B | 443.85B | 470.38B | 457.95B | 444.67B | 531.23B | 520.45B | 545.1B | 541.4B | 419.43B | 354.05B | 319.94B | 291.27B |
EBIT | 488.37B | 444.06B | 443.85B | 470.38B | 457.95B | 444.67B | 531.23B | 520.45B | 545.1B | 541.4B | 419.43B | 354.05B | 319.94B | 291.27B |
Depreciation & Amortization | 2.3B | 2.7B | 2.8B | 1.8B | 2B | 1.9B | 1.7B | 3.2B | 3.1B | 4B | 4B | 9.49B | 9.43B | 8.58B |